Merck U.S. Human Health management
Executive Summary
Merck/Schering Pharmaceuticals General Manager Adam Schechter will succeed Brad Sheares as president of Merck's U.S. Human Health division, effective immediately. In his position heading the Merck/Schering-Plough joint venture, Schechter oversaw initiatives such as the launch of the ezetimibe/simvastatin fixed-dose combination Vytorin in 2004. Sheares, a nearly 20-year veteran of Merck, was appointed president of USHH in 2001 and was seen as one potential successor to CEO Richard Clarke (1"The Pink Sheet" May 9, 2005, p. 14). It is understood that President-Human Health Intercontinental Per Wold-Olsen, also once seen as a possible Clarke successor, has left the company as well...
You may also be interested in...
Merck Taps Clark As CEO In Nod To Medco Heritage; Gilmartin To Retire
Merck's appointment of Richard Clark to succeed retiring CEO Ray Gilmartin continues the Medco legacy at Merck's senior management level
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.